Providing people with the ability to test for viruses in their own homes empowers them to be proactive about their health while helping public health officials, policymakers, and researchers with information that could head off the next pandemic.
Overall median survival was higher in participants taking quizartinib, according to results from QuANTUM-First trial.
Although there's no magic formula for finding the appropriate pharmacy staffing levels, there are subtle shifts you can make that will have a big impact on your bottom line.
This new treatment option copackages 3 drugs for optimal treatment.
The FDA approved a biologics license application for the tick-borne encephalitis (TBE) vaccine TICOVAC for individuals 1 year or older.
The need for skilled and knowledgeable pharmacy technicians in our workforce remains steady throughout current times.
Pharmacogenomics provides an opportunity for pharmacists to enhance their role in patient care.
A variety of nonprescription treatments, supplements, and patches can alleviate pain for children and adolescents.
The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
The existing approach to disease management may be ill-suited to address the dynamic and diverse factors at play when it comes to chronic illness.
An interim FTC report outlined how the rise of vertical integration and concentration has led to devastating results for both patients and fragile pieces of the health care delivery system.
The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.
The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum and fluoropyrimidine-based chemotherapy for the frontline treatment of patients.
A conversation with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia, on RSV vaccine recommendations.
Improvement across all asthma control parameters was achieved after 12 months of biologic treatment with mepolizumab, benralizumab, and omalizumab.
It’s crucial to be openminded about these approaches, and to convey accurate information to patients in a nonjudgmental manner.
A unified data ecosystem will provide the foundation for the next generation of patient-care technology.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
The 2-dose hepatitis B vaccine was not associated with a higher risk of acute myocardial infarction compared with the 3-dose hepatitis B vaccine series.
Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.
On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting.
The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.
Demetre Daskalakis, MD, MPH, urged those in the LGBTQ+ community to get fully vaccinated against the disease.
Beyond improving glucose control, hybrid closed-loop glucose monitoring systems offered indirect benefits like reduced fear of hypoglycemia and improved sleep quality among youth with type 1 diabetes (T1D).
Continuous glucose monitoring has many benefits and can improve disease management in for both diabetes types.
CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.
A lack of diversity in clinical trials has hampered health care providers from understanding the nuances of diseases across specific patient populations.
John Bucheit, PharmD, joined Drug Topics to discuss statins and nonstatins’ efficacy in treating cardiovascular disease.